Sinopharm Group Co. Ltd Cash Flow Conversion Efficiency

Latest as of June 2023: -0.023x

Sinopharm Group Co. Ltd cash flow conversion efficiency. Based on the latest financial reports, Sinopharm Group Co. Ltd (X2S) has a cash flow conversion efficiency ratio of -0.023x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.63 Billion ≈ $-3.08 Billion USD) by net assets (€113.11 Billion ≈ $132.24 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Sinopharm Group Co. Ltd (2013–2025)

Cash flow conversion efficiency of Sinopharm Group Co. Ltd from 2013 to 2025. This chart illustrates how Sinopharm Group Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Sinopharm Group Co. Ltd for real-time trading data and today's change.

Sinopharm Group Co. Ltd Cash Flow Conversion Ratio Explained

Sinopharm Group Co. Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Sinopharm Group Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Sinopharm Group Co. Ltd ranked by their cash flow conversion efficiency. Also see Sinopharm Group Co. Ltd market cap and net worth for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Chongyi Zhangyuan Tungsten Co Ltd SHE:002378	0.096x
Sims Metal Management Ltd F:I8M	0.025x
TIZA Information Industry Corporation Inc SHE:300209	-0.015x
ABM Industries Incorporated NYSE:ABM	0.082x
Aperam SA F:7AA	-0.003x
Jumbo S.A. AT:BELA	0.023x
BBVA Banco Frances SA ADR NYSE:BBAR	0.420x
National HealthCare Corporation NYSE MKT:NHC	0.058x

Annual Cash Flow Conversion Efficiency for Sinopharm Group Co. Ltd (2013–2025)

The table below shows the annual cash flow conversion efficiency of Sinopharm Group Co. Ltd from 2013 to 2025. Review how much free cash does Sinopharm Group Co. Ltd generate to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€134.16 Billion ≈ $156.85 Billion	€14.14 Billion ≈ $16.53 Billion	0.105x	+15.63%
2024-12-31	€126.69 Billion ≈ $148.11 Billion	€11.55 Billion ≈ $13.50 Billion	0.091x	-36.15%
2023-12-31	€120.32 Billion ≈ $140.67 Billion	€17.17 Billion ≈ $20.08 Billion	0.143x	-25.06%
2022-12-31	€110.07 Billion ≈ $128.68 Billion	€20.96 Billion ≈ $24.51 Billion	0.190x	+103.91%
2021-12-31	€99.65 Billion ≈ $116.51 Billion	€9.31 Billion ≈ $10.88 Billion	0.093x	-24.68%
2020-12-31	€89.95 Billion ≈ $105.16 Billion	€11.15 Billion ≈ $13.04 Billion	0.124x	-49.19%
2019-12-31	€76.94 Billion ≈ $89.95 Billion	€18.78 Billion ≈ $21.95 Billion	0.244x	+356.05%
2018-12-31	€68.28 Billion ≈ $79.82 Billion	€3.65 Billion ≈ $4.27 Billion	0.054x	-14.49%
2017-12-31	€51.27 Billion ≈ $59.94 Billion	€3.21 Billion ≈ $3.75 Billion	0.063x	-69.90%
2016-12-31	€44.53 Billion ≈ $52.06 Billion	€9.26 Billion ≈ $10.82 Billion	0.208x	-36.64%
2015-12-31	€40.88 Billion ≈ $47.79 Billion	€13.41 Billion ≈ $15.68 Billion	0.328x	+114.12%
2014-12-31	€36.29 Billion ≈ $42.43 Billion	€5.56 Billion ≈ $6.50 Billion	0.153x	-11.27%
2013-12-31	€28.61 Billion ≈ $33.45 Billion	€4.94 Billion ≈ $5.78 Billion	0.173x	--

About Sinopharm Group Co. Ltd

F:X2S Germany Medical Distribution

Market Cap

$2.96 Billion

€2.53 Billion EUR

Market Cap Rank

#4796 Global

#814 in Germany

Share Price

€1.89

Change (1 day)

+2.95%

52-Week Range

€1.64 - €2.37

All Time High

€2.71